February 20th, 2012, by David Pascoe | in the news, new treatments
News this week that the Japanese company Maruho is to acquire Pennsylvania based Cutanea Life Sciences. Cutanea Life Sciences is developing Omiganan as a treatment for rosacea.
Maruho Co., Ltd. Acquires Cutanea Life Sciences, Inc.
Cutanea to Become a Wholly-Owned Subsidiary of Maruho
OSAKA, Japan, Feb 13, 2012 (GlobeNewswire via COMTEX) — Mr. Koichi Takagi, President and CEO of Maruho Co., Ltd, headquartered in Kita-ku, Osaka, Japan, …
February 16th, 2012, by David Pascoe | new treatments
A recent Forbes article details the truly amazing cost of developing a new drug. Whilst the pharmaceutical company best know to rosacea sufferers – Galderma, is not mentioned in the list of companies R&D spending, we can assume that their costs for the whole of the development cycle for drugs like Sansrosa/CD07805/47 would be comparable.
Even though products like Oracea are too expensive, it is …
December 13th, 2011, by David Pascoe | in the news, new treatments, sansrosa
The Daily Mail continues its interest in rosacea treatments with an article about an unnamed glaucoma treatment that has been formulated as a gel treatment for the redness of rosacea. Of course we know this treatment as Sansrosa. Other names we have seen over the years include COL-118 and CD07805/47. The active ingredient in the glaucoma …
November 21st, 2011, by David Pascoe | in the news, new treatments
The FDA announced today that the U.S. Food and Drug Administration approved 35 new medicines in fiscal year 2011. They included “important advances for patients, including: two new treatments for hepatitis C; a drug for late-stage prostate cancer; …
October 14th, 2011, by David Pascoe | clinical trials, new treatments, red face
A product from Merck designated as MK-0524, also known as Laropiprant, is to be trialled as a treatment for the redness of rosacea. This is great news for rosacea …
